Orexo eyes opioid use disorder app launch before year-end
pharmaphorum
OCTOBER 2, 2020
“Modia is designed to close the gap as it relates to the access and receipt of quality, evidence-based therapeutic interventions and behavioural health services for individuals with OUD who participate in outpatient treatment with MAT,” said Michael Sumner, Orexo’s chief medical officer.
98 
Let's personalize your content